支气管动脉灌注化疗联合栓塞治疗肺癌合并咯血疗效分析

Bronchial arterial infusion embolization for hemoptysis in advanced primary lung cancer

目的探讨支气管动脉灌注化疗联合栓塞治疗肺癌合并咯血的安全性及有效性。方法选取我院2016年6月~2021年10月采用支气管动脉灌注化疗联合栓塞治疗的94例肺癌合并咯血患者的临床及影像资料,评估临床疗效,观察术后不良反应,分析无咯血生存期和总生存期。结果本组肿瘤疗效评估完全缓解(CR)28例(34.6%),部分缓解(PR)41例(50.6%),稳定(SD)9例(11.1%),进展(PD)3例(3.7%),客观缓解率为85.2%,疾病控制率为96.3%。本组患者中位无咯血生存期为9.0月(95%CI:6.87~11.13),中位生存期为10.0月(95%CI:6.83~13.17)。所有不良事件均为1级不良事件。结论支气管动脉灌注化疗联合栓塞治疗肺癌合并咯血安全、有效,可耐受性良好,在临床上是一种可行的姑息性治疗手段。

Objective To evaluate the safety and effectiveness of bronchial artery infusion embolization in the treatment of lung cancer with hemoptysis.Methods The clinical and imaging data of 94 lung cancer patients with hemoptysis admitted to our hospital from June 2016 to December 2021 were retrospectively analyzed.Bronchial artery infusion embolization was used for treatment.We evaluated clinical efficacy,observed postoperative adverse reactions,and analyzed hemoptysis-free survival and overall survival.Results The tumor curative effect evaluation after treatment was CR in 28 cases(34.6%),PR in 41(50.6%)cases,SD in 9(11.1%)cases,and PD in 3(3.7%)cases,the objective response rate was 85.2%,and the disease control rate was 96.3%.The median survival time of patients without hemoptysis was 9.0 months(95%CI 6.87~11.13),and the median survival time was 10.0 months(95%CI 6.83~13.17).All adverse events were grade 1 adverse events.Conclusion Bronchial arterial infusion embolization is safe,effective,and well tolerable in the treatment of lung cancer with hemoptysis.It is a feasible palliative treatment in clinical practice.